(Abstracted from Ultrasound Obstet Gynecol 2018;51:445–452)
Chromosomal microarray is currently recommended for women with fetal structural anomalies. However, questions remain as to whether such testing is justifiable in pregnancies without increased risk for unbalanced structural chromosomal aberrations.
Departments of Clinical Genetics (M.I.S., M.J., S.V.V., D.V.O.) and Obstetrics and Gynecology (M.F.C.M.K., A.T.J.I.G.), Erasmus MC; Foundation Prenatal Screening Southwest Region of the Netherlands (M.F.C.M.K.); Department of Psychology, Education and Child Studies, Erasmus University Rotterdam (L.R.A., M.P.); and Department of Biostatistics, Erasmus MC (L.R.A.), Rotterdam, the Netherlands